Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Upregulation of MAPK/MCL-1 Maintaining Mitochondrial Oxidative Phosphorylation Confers Acquired Resistance to BCL-2 Inhibitor Venetoclax in AML

Qi Zhang, MD PhD, Lina Han, MD PhD, Ce Shi, MD PhD, Rongqing Pan, MS, Man Chun John MA, PhD, Jeremy Ryan, PhD, Stephen E Kurtz, PhD, Hong Mu, MD PhD, Vivian Ruvolo, MS, Helen Ma, MS, Michael Andreeff, MD PhD, Yingchang Mi, MD PhD, Jeffrey W. Tyner, PhD, Joel Leverson, Anthony Letai, MD PhD, Richard Eric Davis, MD, Marina Konopleva, MD PhD

Blood (2016) 128 (22): 101.

https://doi.org/10.1182/blood.V128.22.101.101

Published: 2016

Journal Articles

BCL-2 Inhibition By ABT-199 (Venetoclax/GDC-0199) and p53 Activation By RG7388 (Idasanutlin) Reciprocally Overcome Leukemia Apoptosis Resistance to Either Strategy Alone: Efficacy and Mechanisms

Rongqing Pan, MS, Vivian Ruvolo, MS, Hong Mu, MD PhD, Zhuanzhen Zheng, PhD, Joel Leverson, PhD, Kensuke Kojima, PhD, Marina Konopleva, MD PhD, Gwen Nichols, MD, Michael Andreeff, MD PhD

Blood (2015) 126 (23): 673.

https://doi.org/10.1182/blood.V126.23.673.673

Published: 2015

Journal Articles

Role of Mesenchymal Stem Cell Galectin 3 in the AML Tumor Microenvironment

Peter Ruvolo, PhD, Yihua Qiu, MD, Vivian Ruvolo, MS, Rui-Yu Wang, MD PhD, Zhihong Zeng, MD, Jared Burks, PhD, Rongqing Pan, MS, Numsen Hail, Jr., PhD, Teresa McQueen, Suk-Young Yoo, Steven M. Kornblau, MD, Michael Andreeff, MD PhD

Blood (2015) 126 (23): 1198.

https://doi.org/10.1182/blood.V126.23.1198.1198

Published: 2015

Journal Articles

Mechanisms of Acquired Resistance to Venetoclax in Preclinical AML Models

Qi Zhang, Rongqing Pan, MS, Lina Han, PhD, Ce Shi, PhD, Stephen E. Kurtz, PhD, Hong Mu, MD PhD, Helen Ma, Michael Andreeff, MD PhD, Joel Leverson, PhD, Jeffrey W. Tyner, PhD, Yingchang Mi, MD PhD, Marina Konopleva, MD PhD

Blood (2015) 126 (23): 328.

https://doi.org/10.1182/blood.V126.23.328.328

Published: 2015

Journal Articles

Activation of p53 By Novel MDM2 Antagonist RG7388 Overcomes AML Inherent and Acquired Resistance to Bcl-2 Inhibitor ABT-199 (GDC-0199)

Rongqing Pan, MS, Kensuke Kojima, MD PhD, Zhuanzhen Zheng, MD PhD, Vivian R Ruvolo, MA, Gwen Nichols, MD, Joel D. Leverson, PhD, Markus Dangl, PhD, Marina Konopleva, MD PhD, Michael Andreeff, MD PhD

Blood (2014) 124 (21): 2162.

https://doi.org/10.1182/blood.V124.21.2162.2162

Published: 2014

Journal Articles

Proteomic, Gene Expression, and Micro-RNA Analysis Of Bone Marrow Mesenchymal Stromal Cells In Acute Myeloid Leukemia Identifies Pro-Inflammatory, Pro-Survival Signatures In Vitro and In Vivo

Blood (2013) 122 (21): 3685.

https://doi.org/10.1182/blood.V122.21.3685.3685

Published: 2013

Journal Articles

BCL-2-Selective BH3 Mimetic ABT-199 Is a Potent Agent For Acute Myeloid Leukemia

Rongqing Pan, MS, LaKeisha Debose, MS, Juliana M Benito, PhD, Leonard S Golfman, PhD, Patrick A Zweidler-McKay, MD, PhD, Lina Han, PhD, Karine G. Harutyunyan, PhD, Hong Mu, MD, PhD, Vivian R Ruvolo, MA, Eugene Park, Markus Muschen, MD, PhD, Joel Leverson, PhD, Gautam Borthakur, MD, Hagop M Kantarjian, MD, Peter P. Ruvolo, PhD, Michael Andreeff, MD, PhD, Marina Konopleva, MD, PhD

Blood (2013) 122 (21): 1456.

https://doi.org/10.1182/blood.V122.21.1456.1456

Published: 2013

NARROW

Upregulation of MAPK/MCL-1 Maintaining Mitochondrial Oxidative Phosphorylation Confers Acquired Resistance to BCL-2 Inhibitor Venetoclax in AML

BCL-2 Inhibition By ABT-199 (Venetoclax/GDC-0199) and p53 Activation By RG7388 (Idasanutlin) Reciprocally Overcome Leukemia Apoptosis Resistance to Either Strategy Alone: Efficacy and Mechanisms

Role of Mesenchymal Stem Cell Galectin 3 in the AML Tumor Microenvironment

Mechanisms of Acquired Resistance to Venetoclax in Preclinical AML Models

Activation of p53 By Novel MDM2 Antagonist RG7388 Overcomes AML Inherent and Acquired Resistance to Bcl-2 Inhibitor ABT-199 (GDC-0199)

Proteomic, Gene Expression, and Micro-RNA Analysis Of Bone Marrow Mesenchymal Stromal Cells In Acute Myeloid Leukemia Identifies Pro-Inflammatory, Pro-Survival Signatures In Vitro and In Vivo

BCL-2-Selective BH3 Mimetic ABT-199 Is a Potent Agent For Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Upregulation of MAPK/MCL-1 Maintaining Mitochondrial Oxidative Phosphorylation Confers Acquired Resistance to BCL-2 Inhibitor Venetoclax in AML

BCL-2 Inhibition By ABT-199 (Venetoclax/GDC-0199) and p53 Activation By RG7388 (Idasanutlin) Reciprocally Overcome Leukemia Apoptosis Resistance to Either Strategy Alone: Efficacy and Mechanisms

Role of Mesenchymal Stem Cell Galectin 3 in the AML Tumor Microenvironment

Mechanisms of Acquired Resistance to Venetoclax in Preclinical AML Models

Activation of p53 By Novel MDM2 Antagonist RG7388 Overcomes AML Inherent and Acquired Resistance to Bcl-2 Inhibitor ABT-199 (GDC-0199)

Proteomic, Gene Expression, and Micro-RNA Analysis Of Bone Marrow Mesenchymal Stromal Cells In Acute Myeloid Leukemia Identifies Pro-Inflammatory, Pro-Survival Signatures In Vitro and In Vivo

BCL-2-Selective BH3 Mimetic ABT-199 Is a Potent Agent For Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only